Slide 1: Moderna Investor Update
DNA mRNA Protein Moderna Investor Update October 8, 2020
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: plans for the completion of the Phase 1 study of mRNA-1172 and the transition of the program to
Slide 3: Agenda for today
Moderna October 8th, 2020 Investor Update • RSV update ̶ Moderna regains rights to adult RSV vaccine program from Merck ̶ Merck to focus on their RSV antibody program ̶ Moderna will have the right to advance RSV vaccines in adults, either alone or in combination with other respiratory virus vaccines
Slide 4: Respiratory Syncytial Virus (RSV) Vaccine Program Update
Respiratory Syncytial Virus (RSV) Vaccine Program Update • Moderna regains rights to adult RSV vaccine program from Merck (mRNA-1172 or V172) ̶ Merck will complete the Phase 1 study and transition the program to Moderna ̶ Among its RSV candidates, Merck decided to focus its efforts on RSV infections
Slide 5: DARPA NOW (Nucleic Acids On Demand World-Wide)
DARPA NOW (Nucleic Acids On Demand World-Wide) DARPA awards Moderna up to $56 million to enable small-scale, rapid mobile manufacturing of nucleic acid vaccines and therapeutics DARPA NOW Award • Award part of DARPA’s NOW initiative to develop a medical countermeasure manufacturing platform 1 3 • DA
Slide 6: Statement by Moderna on Intellectual Property Matters During the COVID-19 Pandemic
Statement by Moderna on Intellectual Property Matters During the COVID-19 Pandemic Moderna is a pioneer in the development of messenger RNA (mRNA) vaccines and therapeutics. From its inception in 2010, Moderna saw the potential of this new class of medicines to make a significant difference in patie
Slide 7: Our mission
Our mission To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. Slide 7